



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

NOV 15 2001

RECEIVED

#16

Re PATENT APPLICATION of:

Group Art Unit: 1636

HEERY et al.

Examiner: McKelvey, T

Appln. No.: 09/423,037

Filed: February 22, 2000

FOR: INHIBITORS OF NUCLEAR PROTEIN/NUCLEAR RECEPTOR INTERACTION

Date: November 13, 2001
November 12=Holiday
November 11=Sunday

RESPONSE TO RESTRICTION REQUIREMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

This is in response to the one-month Office Action dated September 11, 2001, the time for responding to which has been extended to and including November 13, 2001 by petition and fee submitted herewith. In response to the restriction requirement set forth therein, applicants hereby elect the invention of Group I, claims 1-13 drawn to a method of identifying inhibitor compounds.

The examiner has also required a provisional election of species, pending allowance of a generic claim. If the examiner's complex requirement has been correctly understood, an election from each of species types 1, 2 and 3 is required with the election of Group I. In accordance with this understanding, applicants hereby provisionally elect:

For the signature sequence: LXXLL

For the coactivator: SRC-1

For the transcription factor: oestrogen receptor.


Claims readable on the provisionally elected species are claims 1, 2, 3, 4, 7, 8, 9, 10, 11, 12 and 13.

The above is believed to be in full compliance with the restriction requirement and requirement for election of species as requested by the examiner. However, if applicants have misunderstood the examiner's intention, it is respectfully requested that the examiner call the undersigned so that any needed supplementation can be quickly provided.

Respectfully Submitted,

PILLSBURY WINTHROP LLP

By:



1600 Tysons Boulevard
McLean, Virginia 22102
Telephone: (703) 905-2000
DJB:mk

Donald J. Bird
Registration No. 25,323
Tel. No.: (703) 905-2018
Fax No.: (703) 905-2500

Inventor(s): HEERY et al.

Appl. No.: 09

423,037

Series Code ↑

Serial No. ↑

Filed: February 22, 2000

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1636

Examiner: McKelvey, T.

Atty. Dkt. P 0264015

Z70228/US

M#

Client Ref

Appl. Title: INHIBITORS OF NUCLEAR
PROTEIN/NUCLEAR RECEPTOR
INTERACTIONDate: November 13, 2001
November 12=Holiday
November 11=Sunday

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☐ made previously

For B & C
See Required
Separate Paper
(Pat-256)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	56	**minus 56	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	1	***minus 3	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)	add			+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: October 11, 2001	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo)	\$110/\$55 =				115/215
	(2 mos)	\$400/\$200 =	+ \$110			116/216
	(3 mos)	\$920/\$460 =				117/217
(Usable only for ≤ 2mo.OA --- 4 mos)		\$1,440/\$720=				118/218
(Usable only for 30 day/1mo.OA --- 5 mos)		\$1,960/\$980=				128/228
7. Enter any previous extension fee paid since above original due date and subtract				- \$0		
8. Extension Fee Attached				+ \$110		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee				+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),	add			+ \$180	+ \$0	126
or if Rule 97(d) Request	add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)				x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)				+ \$740/370	+ \$0	1179/1279
14. Petition fee for				+ \$0		
15. TOTAL FEE ENCLOSED =					\$110	

16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

11/14/2001 TGEDAMU1 00000001 09423037

Our Deposit Account No. 03-3975)

01 FC:115

110.00 OP

(Our Order No. 009901 0264015
C# M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

11/14/2001 TGEDAMU1 00000001 09423037

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

1600 Tysons Boulevard
McLean, VA 22102
Tel: (703) 905-2000
Atty/Sec: DJB/mk

Intellectual Property Group
By Atty: Donald J. Bird

Sig:

Reg. No. 25323

Fax: (703) 905-2500

Tel: (703) 905-2018

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments